back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2025-06-10 14:05 Tx date 2025-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
50 - Grant of options
|
+50,000 vol |
50,000 | |
| Filed 2025-06-10 14:03 Tx date 2014-11-05 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-03-14 13:07 Tx date 2025-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
||
| Filed 2025-03-14 13:07 Tx date 2025-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
1,880,000 | |
| Filed 2025-03-14 13:01 Tx date 2025-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+275,000 vol |
1,830,000 | |
| Filed 2025-01-28 12:32 Tx date 2025-01-27 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
-16,315 vol |
1,555,000 | |
| Filed 2025-01-28 12:31 Tx date 2025-01-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
-22,468 vol |
1,571,315 | |
| Filed 2025-01-28 12:29 Tx date 2025-01-23 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
-16,217 vol |
1,593,783 | |
| Filed 2025-01-28 12:26 Tx date 2025-01-27 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-47,189.43
-1,149 vol $41.07 each |
31,302 | |
| Filed 2025-01-28 12:19 Tx date 2025-01-27 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$20,406
+1,149 vol $17.76 each |
32,451 | |
| Filed 2025-01-28 12:16 Tx date 2025-01-27 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-613,616.36
-15,166 vol $40.46 each |
31,302 | |
| Filed 2025-01-28 12:14 Tx date 2025-01-27 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$269,348
+15,166 vol $17.76 each |
46,468 | |
| Filed 2025-01-28 12:12 Tx date 2025-01-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-903,213.60
-22,468 vol $40.20 each |
31,302 | |
| Filed 2025-01-28 12:11 Tx date 2025-01-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$399,031
+22,468 vol $17.76 each |
53,770 | |
| Filed 2025-01-28 12:08 Tx date 2025-01-23 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-649,977.36
-16,217 vol $40.08 each |
31,302 | |
| Filed 2025-01-28 12:07 Tx date 2025-01-23 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$288,013
+16,217 vol $17.76 each |
47,519 | |
| Filed 2024-10-02 12:44 Tx date 2024-09-27 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Holder: Spouse's Account (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$84,000
+200,000 vol $0.42 each |
313,333 | |
| Filed 2024-04-09 14:52 Tx date 2024-04-03 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$38,250
+45,000 vol $0.85 each |
330,000 | |
| Filed 2024-04-09 14:51 Tx date 2024-04-03 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$38,250
+45,000 vol $0.85 each |
||
| Filed 2024-04-09 14:38 Tx date 2024-04-03 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$38,250
+45,000 vol $0.85 each |
||
| Filed 2023-09-14 18:15 Tx date 2023-03-23 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+45,000 vol |
285,000 | |
| Filed 2023-05-26 19:38 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-58,376.43
-1,407 vol $41.49 each |
31,302 | |
| Filed 2023-05-26 19:37 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
38 - Redemption, retraction, cancellation, repurchase
|
-1,171 vol |
32,709 | |
| Filed 2023-05-26 19:36 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
+6,172 vol |
33,880 | |
| Filed 2023-05-26 19:35 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-545,215.23
-13,179 vol $41.37 each |
27,708 | |
| Filed 2023-05-26 19:35 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
38 - Redemption, retraction, cancellation, repurchase
|
-3,902 vol |
40,887 | |
| Filed 2023-05-26 19:34 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
+20,576 vol |
44,789 | |
| Filed 2023-05-26 19:33 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-707,339.36
-17,069 vol $41.44 each |
24,213 | |
| Filed 2023-05-26 19:31 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
38 - Redemption, retraction, cancellation, repurchase
|
-7,310 vol |
41,282 | |
| Filed 2023-05-26 19:30 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
+42,592 vol |
48,592 | |
| Filed 2023-05-26 19:28 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-60,794.20
-6,172 vol $9.85 each |
1,610,000 | |
| Filed 2023-05-26 19:25 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-202,673.60
-20,576 vol $9.85 each |
1,616,172 | |
| Filed 2023-05-26 19:19 Tx date 2023-05-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-402,068.48
-42,592 vol $9.44 each |
1,636,748 | |
| Filed 2023-03-14 16:53 Tx date 2023-03-10 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+380,000 vol |
1,679,340 | |
| Filed 2022-03-14 16:30 Tx date 2022-03-10 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+400,000 vol |
1,299,340 | |
| Filed 2022-01-31 15:26 Tx date 2022-01-26 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Holder: Spouse's Account (Control or Direction)
|
Warrants
11 - Acquisition or disposition carried out privately
|
+6,000 vol |
92,500 | |
| Filed 2022-01-31 15:25 Tx date 2022-01-26 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Holder: Spouse's Account (Control or Direction)
|
Warrants
11 - Acquisition or disposition carried out privately
|
+24,000 vol |
86,500 | |
| Filed 2022-01-31 15:22 Tx date 2022-01-26 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Holder: Spouse's Account (Control or Direction)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$90,000
+30,000 vol $3.00 each |
113,333 | |
| Filed 2021-12-13 13:57 Tx date 2021-12-08 |
$APLI
Appili Therapeutics Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$31,850
+245,000 vol $0.13 each |
710,000 | |
| Filed 2021-10-28 23:48 Tx date 2021-10-28 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$228,000
+80,000 vol $2.85 each |
240,000 | |
| Filed 2021-06-03 18:46 Tx date 2021-06-03 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$2,320,000
+125,000 vol $18.56 each |
899,340 | |
| Filed 2021-05-08 12:57 Tx date 2021-05-07 |
$APLI
Appili Therapeutics Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$170,800
+140,000 vol $1.22 each |
465,000 | |
| Filed 2021-03-15 17:06 Tx date 2021-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
774,340 | |
| Filed 2020-10-23 18:00 Tx date 2020-10-20 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$132,300
+70,000 vol $1.89 each |
160,000 | |
| Filed 2020-09-18 19:41 Tx date 2020-09-16 |
$APLI
Appili Therapeutics Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$152,600
+140,000 vol $1.09 each |
325,000 | |
| Filed 2020-07-09 09:05 Tx date 2020-07-03 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Holder: Spouse's Account (Control or Direction)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
62,500 | ||
| Filed 2020-07-09 09:04 Tx date 2020-07-03 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Holder: Spouse's Account (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
83,333 | ||
| Filed 2020-07-09 09:03 Tx date 2020-07-03 |
$PINK
Perimeter Medical Imaging AI, Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
90,000 | ||
| Filed 2020-03-16 16:33 Tx date 2020-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+145,000 vol |
674,340 | |
| Filed 2019-12-06 10:44 Tx date 2019-12-02 |
$APLI
Appili Therapeutics Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$77,000
+140,000 vol $0.55 each |
185,000 | |
| Filed 2019-09-19 15:13 Tx date 2019-09-16 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,274,400
+135,000 vol $9.44 each |
529,340 | |
| Filed 2019-06-19 12:33 Tx date 2019-06-13 |
$APLI
Appili Therapeutics Inc. |
Mortimer, Ian Charles
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
45,000 | ||
| Filed 2018-03-13 Tx date 2018-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+105,000 vol |
394,340 | |
| Filed 2017-10-24 Tx date 2017-10-23 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+25,000 vol |
289,340 | |
| Filed 2017-08-14 Tx date 2017-08-10 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Holder: Katie Mortimer (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$29,000
+10,000 vol $2.90 each |
14,300 | |
| Filed 2017-08-14 Tx date 2017-08-10 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$14,225
+5,000 vol $2.85 each |
6,000 | |
| Filed 2017-03-14 Tx date 2017-03-13 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
264,340 | |
| Filed 2016-06-28 Tx date 2016-06-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Holder: Katie Mortimer (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$6,100
+1,000 vol $6.10 each |
1,000 | |
| Filed 2016-06-28 Tx date 2014-11-05 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Holder: Katie Mortimer (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-06-28 Tx date 2016-06-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$6,150
+1,000 vol $6.15 each |
1,000 | |
| Filed 2016-06-28 Tx date 2016-06-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Holder: Katie Mortimer (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$12,500
+2,000 vol $6.25 each |
3,000 | |
| Filed 2016-06-28 Tx date 2014-11-05 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-06-28 Tx date 2016-06-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Holder: Katie Mortimer (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,190
+1,300 vol $6.30 each |
4,300 | |
| Filed 2016-03-11 Tx date 2016-03-11 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
189,340 | |
| Filed 2015-12-21 Tx date 2015-12-18 |
$XENE
Xenon Pharmaceuticals Inc. |
Mortimer, Ian Charles
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+25,000 vol |
149,340 |